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Background: Short in-frame deletions in the second extracellular domain of the cytokine receptor gp130 are the
leading cause of inflammatory hepatocellular adenomas (IHCAs). The deletions render gp130 constitutively active. In
this study we investigate the intracellular signaling potential of one of the most potent constitutively active gp130
mutants (CAgp130) found in IHCAs.
Results: Trafficking and signaling of CAgp130 were studied in stably transfected cell lines that allowed the
inducible expression of CAgp130 fused to fluorescent proteins such as YFP and mCherry. In contrast to the
predominantly highly glycosylated gp130 wild type (WTgp130), CAgp130 is preferentially found in the less
glycosylated high-mannose form. Accordingly, the mutated receptor is retained intracellularly and therefore less
prominently expressed at the cell surface. CAgp130 persistently activates Stat3 despite the presence of the feedback
inhibitor SOCS3 but fails to activate Erk1/2. De novo synthesized CAgp130 signals already from the ER-Golgi
compartment before having reached the plasma membrane. Cell surface expressed and endocytosed CAgp130
do not significantly contribute to signaling. As a consequence, Stat3 activation through CAgp130 cannot be
inhibited by neutralizing gp130 antibodies but through overexpression of a dominant-negative Stat3 mutant.
Conclusion: CAgp130 and WTgp130 differ significantly with respect to glycosylation, trafficking and signaling.
As a consequence of intracellular signaling pharmacological inhibition of CAgp130 will not be achieved by
targeting the receptor extracellularly but by compounds that act from within the cell.
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Glycoprotein 130 (gp130) is the common signal transdu-
cing receptor subunit for the interleukin (IL)-6-type cyto-
kines. Upon stimulation with IL-6 a hexameric complex is
formed comprising two molecules IL-6, IL-6Rα and gp130
respectively [1]. Janus kinases (JAKs) that are associated
with the cytoplasmic part of gp130 get in close proximity
and activate each other. They phosphorylate cytoplasmic
tyrosine (Tyr)-residues of gp130 that serve as recruitment
sites for transcription factors. There are mainly two signal-
ing pathways activated upon IL-6 binding to gp130. The
JAK/Stat pathway leads to activation of signal transducer
and activator of transcription (Stat)-factors 1 and 3. These* Correspondence: mueller-newen@rwth-aachen.de
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unless otherwise stated.translocate into the nucleus and drive transcription of tar-
get genes like the feedback inhibitor suppressor of
cytokine signaling 3 (SOCS3). The MAPK cascade gets
initiated by recruitment and activation of the SH2-domain-
containing tyrosine phosphatase 2 (SHP2) (reviewed in [2]).
Inflammatory hepatocellular adenomas (IHCAs) repre-
sent the most common type of hepatocellular adenoma
with a frequency of 40-50% [3]. They are primarily found
in women and are associated with alcohol abuse, obesity
and intake of oral contraceptives. In 2009 somatic gain-
of-function mutations were discovered in the IL-6ST
gene in IHCAs coding for gp130. The resulting small
in-frame deletions were found in 60% of IHCAs and
are located in one of the binding sites of gp130 for IL-6.
In hepatic cells these gp130 mutants caused ligand-
independent Stat3 phosphorylation [4]. Two years later it
was reported that 12% of IHCAs lacking a mutation in thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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the role of the gp130-Stat3 axis in benign hepatocellular
tumorigenesis [5].
In recent years there have been numerous reports on
the intracellular signaling potential of RTKs like the
epidermal growth factor receptor (EGFR) and G protein-
coupled receptors (GPCRs) like the β2 adrenergic receptor
(β2AR) upon endocytosis (reviewed in [6]). Elaborate ap-
proaches led to the theory of signaling endosomes. Since
then, spatial regulation of signal transduction has received
more and more attention. Several reports focused on
disease-related, mutant cytokine receptors and RTKs that
show constitutive signaling [7,8].
In this study we focus on the most potent among the
small in-frame deletions of gp130 found in IHCAs – del
(Y186-Y190) – that result in constitutively active gp130
(CAgp130). We analyze glycosylation, cell surface expres-
sion and signaling emanating from constitutively active
CAgp130. We find that CAgp130 is a potent Stat3 acti-
vator but fails to activate the MAPK cascade. Newly
synthesized, intracellularly retained receptor is already
able to signal. On the contrary, receptor at the plasma
membrane and endocytosed receptor do not signifi-
cantly contribute to constitutive activity. Our findings
are of importance for potential therapeutic approaches
and may contribute to treatment options for IHCAs.
In a more general context CAgp130 can be used as a
model system to further elucidate the interface of can-
cer and inflammation.
Results
CAgp130 exhibits deviating glycosylation and decreased
cell surface expression compared to WTgp130
To analyze expression and signaling we generated
HEK293 cells that allowed stable and inducible expres-
sion of differentially tagged fluorescent variants of
WTgp130 and CAgp130. Utilizing the Flp-In T-Rex sys-
tem and selecting single clones, cell lines were generated
for expression of YFP-tagged WTgp130 and CAgp130 –
T-REx-293-WTgp130-YFP and T-REx-293CAgp130-YFP
respectively – as well as expression of mCherry-tagged
WTgp130 and CAgp130 – T-REx-293-WTgp130-mCherry
and T-REx-293-CAgp130-mCherry.
For confocal microscopy (Figure 1A) receptor expres-
sion was induced for 48 h with 20 ng/ml doxycycline
(dox). Signals detected in non-treated cells are caused
mainly by cellular autofluorescence. Upon induction there
is a noticeable difference in the receptor distribution be-
tween cells expressing WTgp130 and CAgp130. Whereas
WTgp130 is distributed throughout the cellular mem-
brane systems the mutant CAgp130 is more concentrated
in membrane structures that resemble the ER-Golgi com-
partment. Gp130 is known to be expressed only at very
low levels at the plasma membrane [9]. Therefore, cellsurface expression was analyzed by flow cytometry that is
more sensitive than microscopy.
To verify total and surface receptor expression in a quan-
titative manner, cells stably transfected with mCherry-
tagged variants of both receptors were analyzed by flow
cytometry (Figure 1B). Expression was induced with
20 ng/ml dox for 24 h. Total receptor expression was
assessed by the fluorescent tag. For verification of sur-
face receptor expression non-permeabilized cells were
immunostained with the gp130 antibody (Ab) B-P8
that binds to the WT and mutant receptor. Histograms
in Figure 1B already point to differences between
WTgp130 and CAgp130 concerning cell surface ex-
pression. Both receptors are expressed at comparable
levels (left panels). However, more WTgp130 seems to
reach the cell surface (right panels). Data from FACS
analysis were quantified and depicted in a diagram
representing the induction of overall and surface re-
ceptor expression. The table documents the reduced
cell surface expression of CAgp130 that is evident
from the decreased ratio of surface to overall receptor
expression (Figure 1B). The same experiment performed
with YFP-tagged receptors confirmed the reduced surface
expression of CAgp130 (data not shown).
Verification of receptor induction by Western Blot
(WB) analysis revealed detectable amounts of receptor
already 4 h upon induction with 20 ng/ml dox (Figure 1C).
WTgp130 is detectable as a double band that represents
low and high glycosylated protein and appears mainly in
the high glycosylated and fully processed form as reported
previously [10]. CAgp130, however, is mainly detected in
an immature form. Total cell lysates (TCLs) from both cell
lines were subjected to Endo H treatment (Figure 1D). For
both receptors the lower band shifted upon Endo H treat-
ment and therefore represents the high-mannose form
that has not yet completely been processed in the Golgi
compartment.
CAgp130 is a strong activator of the JAK/Stat axis but
fails to activate the JAK/Erk pathway
In order to investigate signaling properties of CAgp130
and reveal possible deviations in comparison to signaling
emanating from WTgp130 we first verified phosphoryl-
ation of the mutant receptor. T-REx-293-WTgp130-YFP
and T-REx-293-CAgp130-YFP were incubated with dox
to induce receptor expression. To stimulate phosphoryl-
ation of induced WTgp130 and endogenous gp130,
samples were treated with IL-6 and sIL-6Rα as HEK293
cells do not express membrane-bound IL-6Rα. Immuno-
precipitation (IP) was performed with an Ab against a C-
terminal peptide of gp130 that binds to both WTgp130
and CAgp130. As can be seen in Figure 2A induced
WTgp130 gets phosphorylated upon stimulation, whereas








Figure 1 (See legend on next page.)
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Figure 1 Inducible expression of fluorescently labeled variants of WTgp130 and CAgp130. (A) T-REx-293-WTgp130-mCherry and
T-REx-293-CAgp130-mCherry were left untreated or expression was induced with 20 ng/ml dox for 48 h. Cells were fixed and receptor
expression was analyzed by confocal microscopy. The diagrams represent mCherry fluorescence intensities along the length of the
white arrows. Scale bars: 20 μm. (B) T-REx-293-WTgp130-mCherry and T-REx-293-CAgp130-mCherry were left untreated or expression
was induced with 20 ng/ml dox for 24 h. Overall receptor expression was assessed by FACS analysis of the fluorescent tag (left panel)
and surface receptor expression was determined through staining with the gp130 Ab B-P8 and an APC labeled secondary Ab (right
panel). Non-induced cells (filled histograms) were used as negative controls. Bar charts represent means and standard deviations from
three independent experiments. Fold changes in overall and surface receptor expression as well as the ratios of surface to overall receptor expression
were calculated. (C) T-REx-293-WTgp130-YFP and T-REx-293-CAgp130-YFP were left untreated or expression was induced with 20 ng/ml dox for
the indicated periods of time. TCLs were analyzed by immunoblotting using an Ab raised against a C-terminal peptide of gp130 and an actin Ab as
loading control. (D) T-REx-293-WTgp130-YFP and T-REx-293-CAgp130-YFP were incubated with 20 ng/ml dox for 24 h. TCLs were left untreated or
were subjected to endoH digestion. Subsequently, lysates were analyzed by immunoblotting using Abs against GFP/YFP and actin as loading control.
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detected further below (marked by asterisks). For
WTgp130 only the upper, fully processed form (black
arrows) gets phosphorylated as it has reached the cell
surface and responds to the stimulus. In the case of
CAgp130, however, phosphorylation can be detected
just for the lower, immature form (grey arrows). Inter-
estingly phosphorylation of endogenous receptor is
barely detectable upon induction of WTgp130 and
CAgp130.
Activation of Stats was analyzed by detection of pStat3
(Y705), pStat3(S727) and pStat1(Y701) (Figure 2B). Whereas
WTgp130 activates Stat3 and Stat1 only upon stimulation –
in the case of endogenous gp130 – or induction and
stimulation – in the case of stably transfected WTgp130-
YFP – CAgp130 activates both transcription factors
without stimulation (Figure 2B). Furthermore we were
interested to what extent CAgp130 is able to induce
the feedback inhibitor SOCS3 compared to WTgp130.
Parental T-REx-293 cells and T-REx-293-WTgp130-
YFP were pulse-stimulated for 15 min. Upon removal
of the stimulus SOCS3 expression and Stat3 phos-
phorylation were monitored. SOCS3 induced in the case
of T-REx-293 cells was barely detectable (Figure 2C).
However, SOCS3 induced by CAgp130 was detected at
much higher levels that were comparable to SOCS3 trig-
gered in cells expressing induced WTgp130 120 min after
stimulation.
To verify activation of Erk downstream of JAK by
CAgp130 we assessed phosphorylation of the major
players SHP2 and Erk1/2. As expected, endogenous
gp130 can activate SHP2 and Erk only upon stimulation.
In cells additionally expressing WTgp130 as a YFP-tagged
protein activation is stronger upon induction as far more
receptor molecules are available (Figure 2D). Surprisingly
there is just a partial activation of the JAK/Erk axis by
CAgp130. Upon induction of mutant receptor SHP2 gets
heavily phosphorylated. However, there is hardly any acti-
vation of Erk1/2 detectable. Activation of the JAK/Erk cas-
cade by CAgp130 seems to be strictly limited. Similar
observations were made with untagged receptor (data notshown). No activation of Akt above background levels was
detectable in HEK cells expressing CAgp130 (data not
shown).
WTgp130 and CAgp130 show different functionality of
cytoplasmic Tyr-residues
Previous work by Stahl et al. [11] and Gerhartz et al.
[12] has pointed out the importance of individual pTyr
motifs for activation of specific Stat proteins. Using these
pTyr motifs the last four cytoplasmic Tyr-residues were
identified as recruitment sites for Stat3 within the con-
sensus sequence YXXQ. Stat1 was found to be recruited
to the two most distal cytoplasmic Tyr-residues of gp130
and to the more restricted consensus YXPQ. Work of
Schmitz et al. [13] additionally demonstrated differential
contribution of potential recruitment sites for Stat3
activation.
In order to define the contribution of cytoplasmic Tyr-
residues of CAgp130 for activation of Stat proteins and
SHP2 we generated a series of so-called add-back mutants
of CAgp130, where just single cytoplasmic Tyr-residues
are available for signaling (Figure 3A). Furthermore a mu-
tant of CAgp130 without any cytoplasmic Tyr-residues
was generated – CAgp130-6F-YFP – to serve as a negative
control. Constructs encoding WTgp130-YFP, CAgp130-
YFP, CAgp130-6F-YFP and add-back constructs were
transiently transfected in HEK cells stably expressing
IL-6Rα. Transfected cells were subjected to FACS ana-
lysis to verify overall and surface expression of the mu-
tants (Figure 3B). Overall receptor expression was
assessed using the YFP tag and surface receptor was
stained by two different monoclonal Abs targeting dis-
tinct sites on the extracellular part of gp130. Ab B-P8
targets domain 3 (D3) of the extracellular part of
gp130 and detects both WTgp130 and CAgp130. Ab
B-R3 targets D2 of gp130 and does not detect
CAgp130 probably because of the activating deletion
located within this domain. FACS analysis using Ab B-P8 re-
veals a considerably increased amount of surface WTgp130
compared to CAgp130 in agreement with the FACS
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Figure 2 Phosphorylation state and signaling activity of CAgp130. T-REx-293-WTgp130-YFP and T-REx-293-CAgp130-YFP were left untreated
or expression was induced with 0.5 μg/ml (A) or 20 ng/ml (B, C and D) dox for 24 h. Cells were stimulated with 200 U/ml IL-6 and 0.5 μg/ml sIL-6Rα
for 15 min (A), 30 min (B and D) or for the indicated periods of time (C) or left unstimulated. In (C) cells were puls-stimulated and the stimulus
was removed after 15 min of incubation. (A) Gp130 was immunoprecipitated from TCLs using an antibody against the C-terminus of gp130.
Precipitates were analyzed by immunoblotting using Abs against pTyr and gp130. Asterisks mark phosphorylation signal of endogenous
gp130. Black and grey arrows mark the high and low glycosylated form of WTgp130-YFP and CAgp130-YFP respectively. (B) Activation of
the JAK/Stat pathway was analyzed by immunoblotting of TCLs with Abs against pStat3(Y705), pStat3(S727), pStat1(Y701), Stat3, Stat1,
gp130 and actin as loading control. (C) TCLs of depicted cells were analyzed by immunoblotting using Abs against pStat3(Y705), Stat3, gp130, SOCS3
and actin as loading control. For the SOCS3 positive control HEK293 cells were transiently transfected with a SOCS3 encoding plasmid. (D) Activation of
the JAK/Erk pathway was analyzed by immunoblotting of TCLs with Abs against pSHP2, pErk1/2, SHP2, Erk1/2 and gp130.
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mutants do not show any difference in surface expression
compared to CAgp130 indicating that single Tyr-residues
do not have any impact on cell surface expression.
To study effector functions of single pTyr-residues of
CAgp130 on the JAK/Stat axis TCLs were probed for
pStat3(Y705) and pStat1(Y701). As shown in Figure 3C
there are four cytoplasmic Tyr-residues that are able to
bind Stat3 and Stat1 upon phosphorylation. Activation
of Stat3 by CAgp130 exclusively occurs through the four
distal Tyr-residues in line with findings for WTgp130
[12]. The two distal Tyr-residues seem to be favored as
they lead to stronger Stat3 activation than the two
membrane-proximal ones. Stat1 gets also activated through
binding to the four distal Tyr-residues with the second to
last pTyr being the most preferred activation site. STATac-
tivation through the add-back mutants is stronger than
through CAgp130-YFP harboring all Tyr-residues. This
might be a consequence of the fact that the STAT-
activating add-back mutants lack Y759 required for feed-
back inhibition through SOCS3. Thus, CAgp130-YFP is to
a certain extent sensitive to feedback inhibition. Accord-
ingly, upon strong overexpression of SOCS3 signaling of
CAgp130 ceases (data not shown and [14]).
With respect to activation of the JAK/Erk cascade
TCLs of cells transfected with add-back mutants were
probed for SHP2 and Erk phosphorylation (Figure 3D).
In line with results shown in Figure 2D phosphorylation
of SHP2 but not Erk can be detected in cells transfected
with CAgp130. Activation of SHP2 caused by CAgp130
can be definitely assigned to the second Tyr-residue
proximal to the membrane – Y759 – in line with pub-
lished data [11]. In cells transfected with the CAgp130
that only harbors the SHP2 recruitment site SHP2 activa-
tion is even stronger than in cells expressing CAgp130,
still there is no Erk phosphorylation detectable.
De novo synthesized CAgp130 is able to signal from
intracellular compartments before reaching the cell
surface
In order to investigate whether signaling of CAgp130 is
dependent on its localization at the cell surface T-REx-
293-WTgp130-YFP and T-REx-293-CAgp130-YFP weretreated with dox to induce receptor expression. Simul-
taneously cells were treated with 100 ng/ml brefeldin A
to prevent newly synthesized receptor from reaching the
cell surface. Cells were analyzed by flow cytometry.
Overall expression of the receptor was assessed by the
YFP tag (Additional file 1) and cell surface receptor was
detected by the gp130 Ab B-P8 and an APC labeled sec-
ondary Ab. As shown in Figure 4A dox treatment leads
to the increase of receptor surface expression for both
WTgp130 and CAgp130 with less CAgp130 reaching the
plasma membrane. This increase is already detectable
upon 4 h of induction. The combination of induction
and treatment with brefeldin A causes complete reten-
tion of WTgp130 for the first 4 h. According to the
FACS analysis at the 8 h time point a small amount of
WTgp130 escapes retention and appears on the cell sur-
face. In the case of CAgp130 retention seems to be more
efficient probably due to the smaller amount of receptor
that reach the plasma membrane at all. Brefeldin A in
the applied concentration is able to completely retain
CAgp130 within the cell even 8 h after induction. A
considerable amount of surface receptor is detectable
upon 8 h of induction in the vehicle control for
CAgp130.
TCLs of T-REx-293-CAgp130-YFP were subjected to
WB analysis and probed for CAgp130 expression and
Stat3 phosphorylation (Figure 4B). Upon induction in-
creasing amounts of CAgp130 and stimulus-independent
Stat3 phosphorylation can be detected. Upon treatment
with brefeldin A the upper, higher glycosylated receptor
band disappears. Thus, retention of CAgp130 and gen-
eration of an ER-Golgi hybrid compartment prevent
complete glycosylation of the receptor. Nonetheless,
the retained receptor is still able to phosphorylate Stat3
from within the cell.
Capturing CAgp130 at the cell surface does not markedly
influence its signaling activity
After having assessed activity of de novo synthesized,
intracellularly retained CAgp130 we further tried to elu-
cidate whether mutant receptor is able to signal from





Figure 3 Functional analysis of individual cytoplasmic Tyr-residues of CAgp130. (A) Schematic overview of add-back mutants of CAgp130.
EP: extracellular part with depicted del(Y186-Y190), TD: transmembrane domain, CP: cytoplasmic part. HEK293 cells stably expressing IL-6Rα were
transiently transfected with WTgp130-YFP, CAgp130-YFP, CAgp130-6F-YFP or YFP-tagged add-back mutants of CAgp130. (B) Overall receptor expression
was assessed by FACS analysis of the fluorescent tag (right panel). Surface receptor expression was verified using the gp130 Abs B-P8 and B-R3 and an
Alexa633 labeled secondary Ab (left panel). (C) and (D) Cells were stimulated with 200 U/ml IL-6 for the indicated periods of time or left untreated. TCLs were
analyzed by immunoblotting. (C) Activation of the JAK/Stat pathway was verified by Abs against pStat3(Y705), pStat1(Y701), Stat3, Stat1 and actin as loading
control. (D) JAK/Erk pathway activation was assessed using Abs against pSHP2, pErk1/2, SHP2 and Erk1/2.
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AB
Figure 4 Effect on signaling by intracellular retention of de novo synthesized CAgp130. T-REx-293-WTgp130-YFP and T-REx-293-CAgp130-YFP
were left untreated or expression was induced with 20 ng/ml dox for the indicated periods of time. Cells were simultaneously treated with 100 ng/ml
brefeldin A or MeOH (vehicle). (A) Overall receptor expression was assessed by FACS analysis of the fluorescent tag (Additional file 1) and
surface receptor expression was determined through staining with the gp130 Ab B-P8 and an APC labeled secondary Ab. Non-induced
cells (filled histograms) were used as negative controls. (B) TCLs were analyzed by immunoblotting using Abs against pStat3(Y705),
gp130 and actin as loading control.
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undergoes stimulus-independent internalization and that
it is constitutively associated with the AP-2 adaptor
complex. These findings suggest that gp130 is constitu-
tively endocytosed in a clathrin- and therefore dynamin-
dependent way.
In order to elucidate whether endocytosis of CAgp130 is
dependent on dynamin we utilized the dominant-negative
K44A dynamin mutant [16]. To be able to distinguish non-
transfected cells from cells transfected with dynamin, a
construct was generated that allows simultaneous expres-
sion of K44A dynamin and GFP separated by an internal
ribosomal entry site (IRES) – K44Adynamin/GFP.
Initially, we tested functionality of dominant-negative
dynamin by verification of its inhibitory effect on the
dynamin-dependent transferrin uptake in T-REx 293
cells. T-REx 293 cells were transfected with increasing
amounts of K44Adynamin/GFP and incubated with
Alexa647 labeled human transferrin. Figure 5A shows
concomitant increase in dynamin and GFP signals upon
transfection of increasing amounts of K44Adynamin/GFP.Transfected cells were analyzed by flow cytometry. As
shown in Figure 5B with transfection of increasing
amounts of K44Adynamin/GFP more and more counted
cells shift to the GFP+ population and show reduced
Alexa647 fluorescence indicating a reduction in transfer-
rin uptake. Cells not transfected with dynamin were trans-
fected with a construct encoding IRES-GFP in order to
have a GFP+ population where transferrin uptake is not
perturbed.
Next, cells inducibly expressing CAgp130-mCherry were
transfected with increasing amounts of K44Adynamin/GFP.
About 24 h after transfection cells were treated with dox for
24 h and subsequently analyzed by flow cytometry. GFP+
and therefore dynamin transfected cells were analyzed with
respect to overall and surface receptor expression. Overall
receptor expression was verified via the mCherry tag and
surface receptor was monitored using the gp130 Ab B-P8
and an Alexa405 labeled secondary Ab. As shown in
Figure 5C overall receptor expression is not affected by
transfection of dominant-negative dynamin. Non-induced
cells serve as a negative control. On the contrary, the
Figure 5 Effect of dominant-negative dynamin on surface expression and signaling of CAgp130. (A) and (B) T-REx-293 cells were
transiently transfected with increasing amounts of an expression vector encoding dominant-negative K44A dynamin and GFP. (A) TCLs were
analyzed by immunoblotting using Abs against dynamin, GFP and actin as loading control. (B) Cells were incubated with Alexa647 labeled
transferrin. K44A dynamin expression and transferrin uptake were assessed via FACS analysis. (C) and (D) T-REx-293-CAgp130-mCherry were
transfected with increasing amounts of dominant-negative K44A dynamin. Cells were left untreated or expression of CAgp130 was induced
with 20 ng/ml dox for 24 h. (C) Overall receptor expression was assessed by FACS analysis of the fluorescent tag (right panel) and surface receptor
expression was verified using the gp130 Ab B-P8 and an Alexa405 labeled secondary Ab (left panel). (D) TCLs were analyzed by immunoblotting using
Abs against pStat3(Y705), dynamin, gp130 and actin as loading control.
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of increasing amounts of K44Adynamin/GFP. This result
indicates that CAgp130 gets internalized in a dynamin-
dependent way.
To find out whether inhibiting receptor endocytosis
has any effect on signaling of CAgp130 TCLs of cells
transfected with increasing amounts of K44Adynamin/
GFP were subjected to WB analysis and probed for
pStat3 (Figure 5D). Surprisingly, inhibition of endocyto-
sis does not seem to have any effect on signaling. This
result implies that receptor at the cell surface and recep-
tor molecules upon endocytosis do not considerably
contribute to signaling of CAgp130 if they contribute at
all.
Neutralizing gp130 Abs do not impair constitutive activity
of mutant receptor
In order to further substantiate the finding that cell sur-
face as well as endocytosed receptor molecules do not es-
sentially contribute to the constitutive activity of CAgp130
we tried to inhibit mutant receptor with antagonistic
gp130 Abs. The applied Abs used in this study were devel-
oped in previous work by Wijdenes et al. [17] to inhibit
the biological activity of distinct IL-6-type cytokines
through gp130. Taking into account the recent publication
by Sommer et al. [18] where CAgp130 was reported to beinhibited by a gp130 Ab that specifically neutralizes IL-11
signaling, we included the referred Ab B-P4 in our study.
In addition we utilized gp130 Abs B-T2 and B-R3. B-T2
was originally shown to downregulate IL-6 induced signal-
ing and proliferation of a human myeloma cell line. B-R3
was shown to downregulate IL-6 as well as IL-11 induced
signaling. As mentioned before B-R3 targets domain D2
of gp130 and is not able to bind to CAgp130. Thus it
serves in the context of the mutant receptor as a negative
control.
T-REx-293-WTgp130-YFP and T-REx-293-CAgp130-
YFP were treated with dox to induce receptor expression
and were left untreated or were incubated with the
given concentrations of Abs B-P4, B-T2 or B-R3. In
order to analyze the inhibitory effect on WTgp130 ex-
pressing cells stimulation was performed with IL-6 and
sIL-6Rα. Binding of the Abs was verified by FACS ana-
lysis using an APC-tagged secondary Ab (Additional
file 2). TCLs were subjected to WB analysis and probed
for Stat3 phosphorylation (Figure 6A,B). As shown in
Figure 6A IL-6 induced Stat3 phosphorylation can be
inhibited by Abs B-T2 and B-R3 and to some extent
with Ab B-P4 in a dose- and time-dependent manner.
Strikingly there is no effect of any of the neutralizing
Abs on Stat3 phosphorylation caused by CAgp130
(Figure 6B).
AB
Figure 6 Effect of neutralizing gp130 Abs on signaling of CAgp130. T-REx-293-WTgp130-YFP (A) and T-REx-293-CAgp130-YFP (B) were left
untreated or expression was induced with 20 ng/ml dox for the indicated periods of time. Cells were simultaneously incubated with indicated
amounts of neutralizing gp130 Abs and subsequently stimulated with 200 U/ml IL-6 and 0.5 μg/ml sIL-6Rα or left unstimulated. TCLs were analyzed
by immunoblotting using Abs against pStat3(Y705), Stat3, gp130 and actin as loading control.
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activity of CAgp130
In order to downregulate constitutive Stat3 phosphoryl-
ation caused by CAgp130 from within the cell we took
advantage of the dominant-negative Stat3-Y705F mutant.
Stat3-Y705F impairs WT-Stat3 activity in stimulated cells
and was recently reported to act at multiple levels affect-
ing phosphorylation, nuclear translocation and transcrip-
tional activity of WT-Stat3 upon stimulation [19]. Parental
T-REx-293 cells and cells inducibly expressing Stat3-
Y705F-YFP were transfected with equal amounts of
CAgp130-YFP. Upon induction there is an increase in
expression of CAgp130 and ligand-independent Stat3
phosphorylation in T-REx-293 cells over time (Figure 7).
In cells stably transfected with dominant-negative Stat3,
expression of transiently transfected CAgp130 as well as
Stat3-Y705F-YFP is induced upon dox treatment. Stat3-
Y705F-YFP strongly attenuates CAgp130-mediated phos-
phorylation of endogenous Stat3.
Discussion
In this study we focused on the intracellular signaling
activity of CAgp130. We report that de novo synthesized
mutant receptor is able to signal on its way to the
plasma membrane and that neither plasma membranereceptor nor endocytosed receptor significantly contribute
to constitutive activity. Among the most striking charac-
teristics of CAgp130 are deviations in glycosylation and
subcellular distribution compared to WTgp130. The mu-
tant receptor is mainly present in the immature, high-
mannose form and resides at intracellular membranes.
Similar studies have already been performed for a con-
stitutively active mutant of the thrombopoietin receptor
MPL [7], as well as a series of receptor tyrosine kinases
(RTKs) like FLT3-ITD [20] and constitutively active Kit
[21]. Defects on glycoprotein maturation are coupled to
the ER quality control (reviewed in [22]). Incorrectly
folded glycoproteins interact with ER chaperones and
this interaction causes retention within the ER. While
this manuscript was in preparation Schmidt-Arras et al.
reported that ER retention of CAgp130 is mediated by
its interaction with the ER chaperone calnexin confirm-
ing this assumption [23]. Similar studies revealed the
interaction of calnexin with FLT3-ITD, a RTK that was
also reported to show incomplete glycosylation and im-
paired cell surface expression [20]. However, in the case
of FLT3-ITD and several other RTKs inefficient matur-
ation is rather due to constitutive kinase activity and
tyrosine phosphorylation than defective glycosylation.








0 3 6 9 12 24 0 3 6 9 12 24
Figure 7 Effect of dominant-negative Stat3 on signaling of CAgp130. T-REx-293 cells and cells stably transfected with Stat3-Y705F-YFP were
transfected with equal amounts of CAgp130-YFP. Expression of CAgp130 or CAgp130 and Stat3-Y705F was induced with 20 ng/ml dox for the
indicated periods of time. TCLs were analyzed by immunoblotting using Abs against pStat3(Y705), Stat3 and gp130. The detected endogenous
Stat3 serves as loading control.
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have been replaced shows unaltered surface expression
compared to CAgp130. Furthermore retention of CAgp130
does not activate the unfolded protein response (UPR)
[23] – a stress response initiated by the accumulation
of unfolded or misfolded proteins in the ER [reviewed
in [24]). This report is in line with our findings that
show no induction of the chaperone binding immuno-
globulin protein (BiP) upon strong induction of recep-
tor expression (data not shown). In addition we can
confirm that CAgp130 is not primarily degraded by the
proteasome and therefore exclude ER associated degrad-
ation (ERAD) [22]. Preliminary data indicate stabilization
of CAgp130 in the presence of lysosomal inhibitors (data
not shown).
Apart from processing and subcellular distribution we
found further differences between CAgp130 and WTgp130
concerning their signaling activity. The mutant receptor
strongly activates Stat3 and induces the feedback inhibitor
SOCS3, however, it only causes partial activation of the
JAK/Erk cascade. Although SHP2 gets phosphorylated in a
ligand-independent manner there is no Erk activation de-
tectable. A possible explanation for this fact is based on the
limited spatial availability of components of the MAPK
cascade at intracellular membranes. The adaptor protein
Gab1 is necessary for activation of the MAPK cascade
upon stimulation with several cytokines such as IL-6 and
EGF. Gab1 gets recruited to the plasma membrane via its
PH-domain and this recruitment was reported to be
mandatory for its activation [25], making activation of the
JAK/Erk cascade to a process strictly limited to the plasma
membrane. This finding in combination with the low re-
ceptor amount on the cell surface can possibly explain
our unexpected results. Similar observations on spatial
regulation of receptor activity were made in the case ofFLT3-ITD [8]. Targeting of FLT3-ITD to the plasma
membrane actually reversed its signaling activity strongly
activating MAPK and PI3K pathways and diminishing
Stat5 activation. Taken together these data point out
major deviations in the processing-trafficking-signaling
axis between CAgp130 and WTgp130. These differences
can be attributed to an intrinsic glycosylation defect and
do not rely on constitutive phosphorylation.
In order to find out whether CAgp130 shows any intra-
cellular activity we utilized the pharmacological inhibitor
brefeldin A. Here we report that newly synthesized
CAgp130 activates Stat3 before reaching the plasma
membrane, in line with recently published data [23].
This observation is further in line with the finding that
only immature receptor gets phosphorylated in the
case of CAgp130. The observed decrease in Stat3
phosphorylation correlates with the reduction of over-
all receptor amount. Another possible explanation would
be steric hindrance of receptors accumulating in the
brefeldin-induced ER-Golgi compartment. Yet a further
interesting scenario would be that receptors at intracellu-
lar membranes are less potent in activating signaling path-
ways than receptors at the plasma membrane, bringing up
the spatial regulation of receptor activity. Stat3 activation
from within the cell indicates that CAgp130 gets JAK-
associated and exists as an active dimer from its early pro-
cessing stages within the ER. JAKs have been reported to
act as chaperones and enhance cell surface expression for
a series of receptors like MPL [26], the erythropoietin re-
ceptor EPO-R [27] or the Oncostatin M receptor OSM-R
[28]. Binding of JAKs to these receptors seems to mask a
negative regulatory signal, possibly an ER retention signal.
In the case of CAgp130, however, this chaperone activity
of JAKs is not sufficient to facilitate cell surface expres-
sion. Interestingly there is a similar study performed with
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in the ER by use of the KDEL retention sequence and was
shown to be associated with JAK2. However, it was not
able to support factor-independent growth of transfected
cells as already reported for CAgp130 [18]. Intracellular
signaling was first activated by introduction of a disulfide
bond and forced dimerization as it has already been re-
ported for gp130 [29].
In order to verify whether CAgp130 at the plasma
membrane activates Stat3 we utilized three neutraliz-
ing gp130 Abs [17]. B-P4 and B-T2 successfully
bound surface resident CAgp130 but were insuffi-
cient in blocking its signaling activity. B-R3 does not
bind to the mutated receptor. These findings are in
contrast to the results of Sommer et al., who reported
to block CAgp130 by the Ab B-P4 [18]. Based on our
findings we conclude that the mutant receptor which
localizes to the plasma membrane does not signifi-
cantly contribute to constitutive Stat3 activation. In
the light of these controversial experimental findings
it needs to be taken into account that Abs were tested
on different experimental settings and on different
cell lines.
To further investigate intracellular signaling of CAgp130
we utilized dominant-negative dynamin to inhibit receptor
endocytosis. If the endocytosed receptor accounts for a
part of the constitutive activity as it has been shown for
the EGFR (reviewed in [30]) this contribution should be
omitted upon inhibition of the internalization process.
Interestingly we could not detect any effect of impaired
receptor endocytosis on constitutive signaling. Stat3
phosphorylation remained unaltered indicating that the
endocytosed receptor does not contribute to ligand-
independent activity. Our data indicating that surface
bound receptor does not contribute to constitutive ac-
tivity of CAgp130 are in line with already published
data by Schmidt-Arras et al. [23]. However, data con-
cerning endosomal signaling point to different direc-
tions. Given our results we come to the conclusion
that endocytosed receptor does not exert any constitu-
tive activity. On the contrary Schmidt-Arras et al. re-
ports that endosomal signaling represents an essential
part of constitutive signaling. Again there are differ-
ences in the experimental set up that could help
understand this contradictory data. In our first ap-
proaches to inhibit endocytosis we also utilized the in-
hibitor dynasore. However, FACS analysis of treated
cells revealed detrimental effects on cell viability. In a
more elaborate approach we worked with dominant-
negative dynamin. Our results do not rule out the pos-
sibility of endosomal signaling in the case of CAgp130.
Before giving definite answers to this question the pos-
sibility has to be excluded that mutant receptor molecules
can somehow circumvent classical receptor trafficking.Finally we were able to inhibit Stat3 activation emanating
from CAgp130 by transfection of a dominant-negative
Stat3 mutant [19]. Similarly, signaling of CAgp130 can be
blocked through inhibition of JAK1 as has been recently
reported [14].
Conclusions
Newly synthesized CAgp130 is able to phosphorylate
Stat3 already before reaching the cell surface. Neither
neutralizing gp130 Abs nor inhibition of endocytosis is
able to alter constitutive activity of the mutant receptor.
These findings lead us to the conclusion that surface
resident as well as endocytosed receptor do not signifi-
cantly contribute to the ligand-independent and constitu-
tive activity of CAgp130. Thus, pharmacological inhibition
of CAgp130 can be most efficiently achieved by com-




Restriction enzymes and Endo H (New England Biolabs,
Ipswich, MA, USA), oligonucleotides (MWG-Biotech,
Ebersberg, Germany), doxycycline hyclate and brefeldin
A (Sigma-Aldrich), Alexa Fluor 647 conjugate of human
transferrin (Invitrogen). Recombinant human IL-6 and
sIL-6Rα were expressed and purified as previously de-
scribed [31,32].
Plasmid constructs
Plasmid pSVL-WTgp130-YFP [33] was digested with
XhoI and BamHI and the obtained fragment was
cloned into pcDNA5/FRT/TOspecial (harbors a modi-
fied MCS) resulting in the plasmid pcDNA5/FRT/TOs-
pecial-WTgp130-YFP. For generation of CAgp130 harboring
the deletion Y186-Y190 within domain D2 of gp130 fu-
sion PCR was performed using pcDNA5/FRT/TOspe-
cial-WTgp130-YFP as a template. In the first step two
independent PCRs were performed on the sequences
flanking the sequence to be deleted. Two primer-pairs
were designed – one for the left and one for the right
side of the deletion with complementary overhangs at
the fusion site (in bold): senseP1 – 5’-AGC CTC CGG
ACT CTA GCG-3’, antisenseP1 – 5’-TTC AAT GTT
AAC AAA ATC AAC AGT GCA TGA GGT GGG-3’,
senseP2 – 5’-ACT GTT GAT TTT GTT AAC ATT
GAA GTC TGG G-3’, antisenseP2 – 5’-CCC TCT TAA
ATA GGT GCG-3’. Through substitution of a single
base (underlined) resulting in a silent mutation a HpaI
restriction site was generated to easily distinguish
CAgp130 from WTgp130 constructs. Next, the fusion
PCR was performed using primers senseP1 and antisen-
seP2. The PCR product was first subcloned into pCR2.1-
Topo. The resulting plasmid pCR2.1-Topo-CAgp130 was
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FRT/TOspecial-WTgp130-YFP generating the plasmid
pcDNA5/FRT/TOspecial-CAgp130-YFP.
For generation of mCherry-tagged receptor constructs
mCherry-cDNA was amplified by PCR using the plasmid
pcDNA5/FRT/TOspecial-Stat3-mCherry (previously con-
structed in our lab) as a template: senseP – 5’-CCG GTC
GCG ATA TCG GTG AGC AAG GGC GAG GAG-3’,
antisenseP – 5’-AGA GTC GCG GAT CCT TTA CTT
GTA CAG CTC GTC C-3’. The PCR product was sub-
cloned into pCR2.1-TOPO and the resulting plasmid was
digested with EcoRV and BamHI. The generated fragment
was cloned into pcDNA5/FRT/TOspecial-WTgp130-YFP
resulting in the plasmid pcDNA5/FRT/TOspecial-
WTgp130-mCherry. For generation of mCherry-tagged
CAgp130 the fragment that resulted from XhoI and
Asp718 digestion of pCR2.1-Topo-CAgp130 (see above)
was cloned into pcDNA5/FRT/TOspecial-WTgp130-
mCherry generating the plasmid pcDNA5/FRT/TOspecial-
CAgp130-mCherry.
For generation of add-back mutants of CAgp130 pre-
viously constructed plasmids were used [13]. New con-
structs were generated by three-fragment-ligation. The
backbone was generated by XhoI and EcoRV digestion
of pcDNA5/FRT/TOspecial-WTgp130-YFP. The extra-
cellular part of CAgp130 was isolated upon XhoI and
EcoRI digestion of pcDNA5/FRT/TOspecial-CAgp130-
YFP. The intracellular part of gp130 harboring mutated
Tyr-residues was generated by EcoRI and EcoRV diges-
tion of the preexisting constructs. Following constructs
were generated: pcDNA5/FRT/TOspecial-CAgp130-6F-
YFP, -CAgp130-Y915-YFP, -CAgp130-Y905-YFP, -CAgp130-
Y814-YFP, -CAgp130-Y767-YFP, -CAgp130-Y759-YFP
and -CAgp130-Y683-YFP.
For generation of the K44A dynamin construct the
plasmid pMSCV-IRES-GFP (kindly provided by Dr. N.
Chatain) was digested with EcoRI and SalI and the gen-
erated fragment was cloned into EcoRI and XhoI digested
pcDNA3.1(+). SalI and XhoI generate complementary
overhangs and upon ligation both restriction sites are
destroyed resulting in the plasmid pcDNA3.1(+)-IRES-
GFP. Plasmid pcDNA3.1(+)-IRES-GFP was digested with
BamHI and EcoRI providing the backbone for the next clon-
ing step. The construct pcDNA3.1(−)-HA-hu-dynamin-
K44A (kindly provided by Dr. S. Wüller) was digested
with BamHI and NheI to isolate the N-terminal part of
HA-hu-dynamin-K44A. To generate an EcoRI site and
amplify the C-terminal part of HA-hu-dynamin-K44A
PCR was performed on pcDNA3.1(−)-HA-hu-dynamin-
K44A: senseP – 5’-CGA GCA AGC ATA TCT TTG CC-
3’, antisenseP – 5’-GCA TCG AAT TCT TAG AGG TCG
AAG GGG GGC-3’. The plasmid pcDNA3.1(+)-HA-hu-
dynamin-K44A-IRES-GFP was generated by three-fragment-
ligation. All constructs were verified by sequencing.Cell culture, transient and stable transfection
HEK293 cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) with Glutamax (Gibco, Germany)
supplemented with 10% FCS (Lonza, Germany), 60 mg/l
penicillin and 100 mg/l streptomycin (Gibco, Germany).
For HEK293 cells stably expressing IL-6Rα (kindly pro-
vided by Dr. Anna Dittrich) medium was supplemented
with 2 mg/l Puromycin (Invivogen, CA, USA). Transient
transfections were performed with TransIT-LT-1 trans-
fection reagent (Mirus, Madison, USA). T-REx-293 cells
were stably tranfected using the Flp-In system (Invitro-
gen). Antibiotics for generation and maintenance of
stable cell lines – blasticidin, zeocin, hygromycin B –
were purchased from Invivogen.
Preparation of cell lysates, SDS-PAGE and
immunoblotting
Receptor expression was induced with 20 ng/ml or
0.5 μg/ml dox. Stimulation was performed with 200 U/ml
IL-6 and 0.5 μg/ml sIL-6Rα (when needed). Upon
treatment cells were washed with PBS (150 mM NaCl,
2.5 mM KCl, 8.0 mM Na2HPO4, 1.5 mM KH2PO4, ad-
justed to pH 7.4) and lysed with RIPA lysis buffer
(50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM EDTA,
0.5% Nonidet P40, 1 mM NaF, 15% glycerol) supple-
mented with phosphatase- and protease-inhibitors (1 mM
Na3VO4, 0.25 mM phenylmethylsulfonylfluoride (PMSF),
0.5 mM EDTA, 5 μg/ml aprotinin, 1 μg/ml leupeptin).
Protein concentration was measured using the Bio-Rad
protein assay (Bio-Rad, Germany). Lysates were subjected
to SDS-PAGE, Western Blotting and immunodetection
using Abs against pStat3(Y705), pStat3(S727), pStat1
(Y701), pSHP2(Tyr542), pErk1/2(Thr202/Tyr204), Stat1,
SHP2, Erk1/2 (Cell signaling, USA), Stat3 (BD transduc-
tion laboratories), gp130, SOCS3, dynamin, actin (Santa
Cruz Biotechnology, USA), GFP (Rockland, USA) and
horseradish-peroxidase conjugated secondary antibodies
(DAKO, Denmark). Primary Abs were diluted 1:1000 and
secondary Abs 1:2000 in TBS-N buffer (20 mM Tris–HCl
pH 7.6, 140 mM NaCl, 0.1% Nonidet P40). For pTyr
detection a mixture of two pTyr Abs was used: pY99
(Santa Cruz Biotechnology) (dilution 1:1000) and 4G10
(Millipore, Germany) (dilution 1:10000). Bound Abs
were detected by enhanced chemiluminescence (ECL,
Millipore, USA).
Immunoprecipitation
Cell lysates were incubated o/n with 1 μg gp130 Ab
M20 (Santa Cruz Biotechnology, USA). Subsequently the
lysate-Ab-mixture was incubated o/n with 10 μl Dyna-
beads Protein G (Life Technologies, USA). Immobilized
immune complexes were washed three times with RIPA
lysis buffer, boiled in Laemmli buffer and subjected to
SDS-PAGE and immunoblotting.
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Cells were washed with PBS, detached from the plate for
10 min with PBS/EDTA (10 mM), collected and washed
with FACS buffer (PBS containing 5% FCS and 0.1%
NaN3). Detection of surface receptor was performed
with monoclonal mouse gp130 Abs – B-P8, B-P4, B-T2
and B-R3 – and followed by goat-a-mouse APC- (Dianova,
Hamburg, Germany)/Alexa633-/Alexa405- (Invitrogen) con-
jugated secondary Abs as stated in each case. Abs against
gp130 were kindly provided by Dr. J. Wijdenes. Abs
were applied in a 1:100 dilution in FACS buffer. Cells
were analyzed with a FACSCanto II or a LSR Fortessa
(BD Biosciences). All steps were performed on ice and
with ice-cold solutions.Confocal microscopy
Cells were grown on poly-l-lysine coated coverslips. Fix-
ation of cells has been described previously [19]. Con-
focal imaging was performed with a Zeiss LSM 710
confocal microscope (Zeiss, Jena, Germany). mCherry
fluorescence was detected using the 561 nm laser and a
578-696 nm bandpass filter. The cells were examined
with a Zeiss LD C-apochromat 40×/1.1 water objective.
Confocal images represent confocal slices of approxi-
mately 1 μm.Additional files
Additional file 1: Effect of intracellular retention of de novo synthesized
CAgp130 on overall receptor expression. T-REx-293-WTgp130-YFP and
T-REx-293-CAgp130-YFP were left untreated or expression was induced with
20 ng/ml dox for the indicated periods of time. Cells were simultaneously
treated with 100 ng/ml brefeldin A or MeOH (vehicle). Overall receptor
expression was assessed by FACS analysis of the fluorescent tag. Non-induced
cells (filled histograms) were used as negative controls.
Additional file 2: Binding of neutralizing gp130 Abs to
WTgp130 and CAgp130. T-REx-293-WTgp130-YFP (upper panel)
and T-REx-293-CAgp130-YFP (lower panel) were not incubated with
dox (dotted line) or expression was induced with 20 ng/ml dox for
24 h (solid line). Surface receptor was stained with gp130 Abs B-P8,
B-P4, B-T2 and B-R3 and binding of primary Abs was assessed by an
APC labeled secondary Ab. Non-treated cells (filled histograms)
serve as negative controls.
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